University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Nina Shah, MD

Nina Shah, MD

Associate Professor, Department of Medicine, UCSF

Cancer Center Program Memberships

Hematopoietic Malignancies

Research Summary

Dr. Nina Shah is a hematologist who specializes in the treatment of multiple myeloma, a type of cancer affecting the blood marrow. She treats patients at the Hematology and Blood Marrow and Transplant Clinic.

Nina received a bachelor’s degree in cognitive neuroscience at Harvard University, followed by a medical degree from New York University School of Medicine. She then completed a residency in internal medicine at Columbia University and a fellowship in hematology/oncology at University of Texas MD Anderson Cancer Center.

Nina’s areas of professional interest include the intersection of immunology and oncology and helping patients fight multiple myeloma by boosting their immune systems.

An associate professor at UCSF, Dr. Shah belongs to the American Society of Clinical Oncology, the American Society of Hematology and the American Society for Blood and Marrow Transplantation. She speaks Bengali and Spanish.

Education

Harvard University, Cambridge, MA, BA, 6/1998, Psychology & Biology (Cognitive Neuroscience)
New York University School of Medicine, New York, NY, MD, 5/2002, Doctorate of Medicine
Columbia University Medical Center, New York, NY, Residency, 6/2005, Internal Medicine
Columbia University Medical Center, New York, NY Post-Doctoral Research Fellow, 6/2007, Immunology
The University of Texas MD Anderson Cancer Center, Hematology Oncology, 7/2010, Hematology/Oncology


Professional Experience

  • 2017-present
    Associate Professor, Department of Medicine, University of California San Francisco, San Francisco, CA
  • 2016-2017
    Associate Professor, Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
  • 2010-2016
    Assistant Professor, Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
  • 2014-2016
    Center Medical Director, Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Honors & Awards

  • 2001
    Alfred B. Kornblut Medical Scholarship, New York University School of Medicine
  • 2002
    Alpha Omega Alpha Medical Honor Society, New York University School of Medicine
  • 2002
    Augusta Landes Packer Award, New York University School of Medicine
  • 2002
    New York University School of Medicine Alumni Award, New York University School of Medicine
  • 2005-2007
    Empire Clinical Research Investigator Program Grant, Columbia University
  • 2008
    American Association for Cancer Research/American Society of Clinical Oncology Methods in Clinical Cancer Research Workshop, U. T. M. D. Anderson Cancer Center
  • 2008
    Clifton D. Howe Award for Clinical Excellence, U. T. M. D. Anderson Cancer Center
  • 2008-2012
    Paul Calabresi Clinical Oncology Award Program, Columbia University
  • 2009
    American Society of Hematology Clinical Research Training Institute, U. T. M. D. Anderson Cancer Center
  • 2009
    Lyndon B. Johnson Medical Oncology Service Fellow of the Year, U. T. M. D. Anderson Cancer Center
  • 2009
    The Janice Davis Singletary Fellowship for Lymphoma Research, U. T. M. D. Anderson Cancer Center

Selected Publications

  1. Martinez-Lopez J, Wong SW, Shah N, Bahri N, Zhou K, Sheng Y, Huang CY, Martin T, Wolf J. Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma. Blood Adv. 2020 Jul 28; 4(14):3295-3301.
    View on PubMed
  2. Ramkumar P, Abarientos AB, Tian R, Seyler M, Leong JT, Chen M, Choudhry P, Hechler T, Shah N, Wong SW, Martin TG, Wolf JL, Roybal KT, Pahl A, Taunton J, Wiita AP, Kampmann M. CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma. Blood Adv. 2020 Jul 14; 4(13):2899-2911.
    View on PubMed
  3. Bar M, Ott SM, Lewiecki EM, Sarafoglou K, Wu JY, Thompson MJ, Vaux JJ, Dean DR, Saag KG, Hashmi SK, Inamoto Y, Dholaria BR, Kharfan-Dabaja MA, Nagler A, Rodriguez C, Hamilton BK, Shah N, Flowers MED, Savani BN, Carpenter PA. Bone Health Management After Hematopoietic Cell Transplantation: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2020 Jul 09.
    View on PubMed
  4. Shah N, Aiello J, Avigan DE, Berdeja JG, Borrello IM, Chari A, Cohen AD, Ganapathi K, Gray L, Green D, Krishnan A, Lin Y, Manasanch E, Munshi NC, Nooka AK, Rapoport AP, Smith EL, Vij R, Dhodapkar M. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma. J Immunother Cancer. 2020 Jul; 8(2).
    View on PubMed
  5. Olson AL, Saliba RM, Oran B, Chen J, Alousi A, Ahmed S, Bashir Q, Ciurea SO, Hosing C, Seon Im J, Kebriaei P, Khouri IF, Mehta R, Nieto Y, Parmar S, Rezvani K, Shah N, Shpall E, Srour SA, Qazilbash M, Andersson BS, Champlin R, Popat UR. Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia. Acta Haematol. 2020 Jun 30; 1-8.
    View on PubMed
  6. Holstein SA, Howard A, Avigan D, Bhutani M, Cohen AD, Costa LJ, Dhodapkar MV, Gay F, Gormley N, Green DJ, Hillengass J, Korde N, Li Z, Mailankody S, Neri P, Parekh S, Pasquini MC, Puig N, Roodman GD, Samur MK, Shah N, Shah UA, Shi Q, Spencer A, Suman VJ, Usmani SZ, McCarthy PL. Summary of the 2019 BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. Biol Blood Marrow Transplant. 2020 Jun 23.
    View on PubMed
  7. Shah N. Advances in CAR T-cell therapy for the treatment of multiple myeloma. Clin Adv Hematol Oncol. 2020 Jun; 18(6):316-318.
    View on PubMed
  8. Alonso R, Cedena MT, Wong S, Shah N, Ríos-Tamayo R, Moraleda JM, López-Jiménez J, García C, Bahri N, Valeri A, Sánchez R, Collado-Yurrita L, Martin T, Wolf J, Lahuerta JJ, Martínez-López J. Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma. Blood Adv. 2020 May 26; 4(10):2163-2171.
    View on PubMed
  9. Voorhees PM, Kaufman JL, Laubach JP, Sborov DW, Reeves B, Rodriguez C, Chari A, Silbermann R, Costa LJ, Anderson LD, Nathwani N, Shah N, Efebera YA, Holstein SA, Costello C, Jakubowiak A, Wildes T, Orlowski RZ, Shain KH, Cowan AJ, Murphy SP, Lutska Y, Pei H, Ukropec J, Vermeulen J, de Boer C, Hoehn D, Lin T, Richardson PG. Daratumumab, Lenalidomide, Bortezomib, & Dexamethasone for Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN. Blood. 2020 04 23.
    View on PubMed
  10. Huang HH, Ferguson ID, Thornton AM, Bastola P, Lam C, Lin YT, Choudhry P, Mariano MC, Marcoulis MD, Teo CF, Malato J, Phojanakong PJ, Martin TG, Wolf JL, Wong SW, Shah N, Hann B, Brooks AN, Wiita AP. Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma. Nat Commun. 2020 Apr 22; 11(1):1931.
    View on PubMed
  11. Dhakal B, Patel S, Girnius S, Bachegowda L, Fraser R, Davila O, Kanate AS, Assal A, Hanbali A, Bashey A, Pawarode A, Freytes CO, Lee C, Vesole D, Cornell RF, Hildebrandt GC, Murthy HS, Lazarus HM, Cerny J, Yared JA, Schriber J, Berdeja J, Stockerl-Goldstein K, Meehan K, Holmberg L, Solh M, Diaz MA, Kharfan-Dabaja MA, Farhadfar N, Bashir Q, Munker R, Olsson RF, Gale RP, Bayer RL, Seo S, Chhabra S, Hashmi S, Badawy SM, Nishihori T, Gonsalves W, Nieto Y, Efebera Y, Kumar S, Shah N, Qazilbash M, Hari P, D'Souza A. Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. Leukemia. 2020 Apr 20.
    View on PubMed
  12. Shah N, Chari A, Scott E, Mezzi K, Usmani SZ. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia. 2020 Apr; 34(4):985-1005.
    View on PubMed
  13. Kambhampati S, Galligan D, Huang CY, Wong S, Wolf J, Martin T, Shah N. A single-center retrospective cohort analysis of venetoclax in relapsed/refractory multiple myeloma. Leuk Lymphoma. 2020 May; 61(5):1211-1219.
    View on PubMed
  14. Shah N. The Struggle Is Real: Practice Patterns for the "Myelennial" Generation. JCO Oncol Pract. 2020 01; 16(1):17-18.
    View on PubMed
  15. Sidana S, Shah N. CAR T-cell therapy: is it prime time in myeloma? Hematology Am Soc Hematol Educ Program. 2019 12 06; 2019(1):260-265.
    View on PubMed
  16. Shah EE, Young RP, Wong SW, Damon LE, Wolf JL, Shah ND, Leavitt AD, Loeffler P, Martin TG. Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma. Biol Blood Marrow Transplant. 2020 May; 26(5):876-883.
    View on PubMed
  17. Fakhri B, Fiala MA, Shah N, Vij R, Wildes TM. Measuring cardiopulmonary complications of carfilzomib treatment and associated risk factors using the SEER-Medicare database. Cancer. 2020 Feb 15; 126(4):808-813.
    View on PubMed
  18. Sidana S, Shah N. CAR T-cell therapy: is it prime time in myeloma? Blood Adv. 2019 11 12; 3(21):3473-3480.
    View on PubMed
  19. Efebera YA, Shah N. Fixed-Duration Versus Until Disease Progression: How Long Should Initial Treatment of Multiple Myeloma Last? J Natl Compr Canc Netw. 2019 11; 17(11.5):1430-1432.
    View on PubMed
  20. Choudhry P, Mariano MC, Geng H, Martin TG, Wolf JL, Wong SW, Shah N, Wiita AP. DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma. Leukemia. 2020 Mar; 34(3):938-941.
    View on PubMed

Go to UCSF Profiles, powered by CTSI